IL-2 gene C/T polymorphism is associated with prostate cancer

Journal of Clinical Laboratory Analysis

Volumn 20, Issue 6, 2006, Pages 245-249

  Wu, Hsi Chin ^a   Chang, Chao Hsiang ^a   Wan, Lei ^a   Wu, Chao I ^a   Tsai, Fuu Jen ^a   Chen, Wen Chi ^a  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Interleukin 2 gene (IL 2); Interleukin 2 receptor gene (IL 2 R); Prostate cancer; Single nucleotide polymorphisms (SNPs)

Indexed keywords

CYTOKINE; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR BETA;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DISEASE ASSOCIATION; FOLLOW UP; GENE; GENE FREQUENCY; GENE LOCATION; GENETIC ASSOCIATION; GENOTYPE PHENOTYPE CORRELATION; HOMOZYGOTE; HUMAN; HUMAN TISSUE; INTERLEUKIN 2 GENE; INTERLEUKIN 2 RECEPTOR BETA GENE; LOG RANK TEST; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; POPULATION GENETICS; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE; TAIWAN;

AGED; CASE-CONTROL STUDIES; EXONS; GENE FREQUENCY; GENOTYPE; HOMOZYGOTE; HUMANS; INTERLEUKIN-2; INTERLEUKIN-2 RECEPTOR BETA SUBUNIT; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TAIWAN;

EID: 33845250686     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.20149     Document Type: Article

References (17)

1. Harris DT, Matyas GR, Gomella LG, et al. Immunologic approaches to the treatment of prostate cancer. Semin Oncol 1999;26:439-447.
2. Dolman CS, Mueller BM, Lode HN, Xiang R, Gillies SD, Reisfeld RA. Suppression of human prostate carcinoma metastases in severe combined immunodeficient mice by interleukin 2 immunocytokine therapy. Clin Cancer Res 1998;4:2551-2257.
3. Horak I. Immunodeficiency in IL-2-knockout mice. Clin Immunol Immunopathol 1995;76:S172-S173.
4. Matesanz F, Fedetz M, Collado-Romero M, et al. Allelic expression and interleukin-2 polymorphisms in multiple sclerosis. J Neuroimmunol 2001;119:101-105.
5. Sadlack B, Lohler J, Schorle H, et al. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+T cells. Eur J Immunol 1995;25:3053-3059.
6. Royuela M, De Miguel MP, Bethencourt FR, Fraile B, Arenas MI, Paniagua R. IL-2, its receptors, and bcl-2 and bax genes in normal, hyperplastic and carcinomatous human prostates: immunohistochemical comparative analysis. Growth Factors 2000;18:135-146.
7. Matesanz F, Alcina A, Pellicer A. A new cDNA sequence for the murine interleukin-2 gene. Biochim Biophys Acta 1992;1132:335-336.
8. Matesanz F, Alcina A, Pellicer A. Existence of at least five interleukin-2 molecules in different mouse strains. Immunogenetics 1993;38:300-303.
9. Matesanz F, Alcina A. Induction of autoantibodies to different interleukin-2 allotypes. J Autoimmun 1999;12:221-227.
10. Matesanzl F, Delgado C, Fresno M, Alcinal A. Allelic selection of human IL-2 gene. Eur J Immunol 2000;30:3516-3521.
11. Aus G, Abbou CC, Pacik D, et al. EAU guidelines on prostate cancer. Eur Urol 2001;40:97-101.
12. Moody DB, Robinson JC, Ewing CM, Lazenby AJ, Isaacs WB. Interleukin-2 transfected prostate cancer cells generate a local antitumor effect in vivo. Prostate 1994;24:244-251.
13. Hrouda D, Dalgleish AG. Gene therapy for prostate cancer. Gene Ther 1996;3:845-852.
14. Belldegrun A, Tso CL, Zisman A, et al. Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum Gene Ther 2001;12:883-892.
15. Triest JA, Grignon DJ, Cher ML, et al. Systemic interleukin 2 therapy for human prostate tumors in a nude mouse model. Clin Cancer Res 1998;4:2009-2014.
16. Hautmann SH, Huland E, Huland H. Local intratumor immunotherapy of prostate cancer with interleukin-2 reduces tumor growth. Anticancer Res 1999;19:2661-2663.
17. Lloyd SN, McClinton S, Brown IL, et al. Epidermal growth factor receptor, nuclear proliferation antigen and interleukin-2 receptor expression in prostatic cancer. J Clin Lab Immunol 1990;32:55-58.